Researchers in Hyderabad, India have developed a new synthesis method for creating potent anti-breast cancer agents. The researchers synthesized a series of compounds containing fused [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine using a Cu(I)-catalyzed [3+2] cycloaddition method. These compounds were then tested in vitro against breast cancer cell lines, and several showed significant activity, surpassing the standard drug Erlotinib. In addition, molecular docking studies and ADMET predictions were performed to support the wet lab results. This research provides promising insights into potential treatments for breast cancer. [Extracted from the article]